[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603134":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":19,"locations":24,"responsibleParty":101,"collaborators":7,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":7,"eligibilityCriteria":108,"healthyVolunteers":105,"sex":109,"minAge":110,"maxAge":7,"enrollmentInfo":111,"targetDuration":7,"studyType":114,"phases":7,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Kyowa Kirin Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":12},"DRUG","Poteligeo 20mg",[13],"Mogamulizumab",[15],{"name":16,"affiliation":17,"role":18},"HaeMi Park","Kyowa Kirin Korea Co., Ltd.","STUDY_DIRECTOR",[20],{"name":16,"role":21,"phone":22,"phoneExt":7,"email":23},"CONTACT","+82-10-3378-3471","haemi.park.m8@kyowakirin.com",[25,46,55,67,79,91],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":7,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Kosin University Gospel Hospital","RECRUITING","Busan","Busan Metropolitan City","49267","South Korea",{"type":33,"coordinates":34},"Point",[35,36],129.03004,35.10168,{"lat":36,"lon":35},[39,43],{"name":40,"role":21,"phone":41,"phoneExt":7,"email":42},"Kosin University Gospel Hospital hemato oncology","+82-51-990-6770","hs52silver@gmail.com",{"name":44,"role":45,"phone":7,"phoneExt":7,"email":7},"Ho Sup Lee","PRINCIPAL_INVESTIGATOR",{"facility":47,"status":48,"city":49,"state":7,"zip":7,"country":31,"countryCode":7,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"Chung-Ang University Hospital","TERMINATED","Seoul",{"type":33,"coordinates":51},[52,53],126.9784,37.566,{"lat":53,"lon":52},{"facility":56,"status":27,"city":49,"state":7,"zip":7,"country":31,"countryCode":7,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Ewha Womans University Mokdong Hospital",{"type":33,"coordinates":58},[52,53],{"lat":53,"lon":52},[61,65],{"name":62,"role":21,"phone":63,"phoneExt":7,"email":64},"Ewha Womans University Mokdong Hospital hemato oncology","+82-2-2650-5063","yeungchul@ehwa.ac.kr",{"name":66,"role":45,"phone":7,"phoneExt":7,"email":7},"Yeungchul Moon",{"facility":68,"status":27,"city":49,"state":7,"zip":7,"country":31,"countryCode":7,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"Samsung Medical Center",{"type":33,"coordinates":70},[52,53],{"lat":53,"lon":52},[73,77],{"name":74,"role":21,"phone":75,"phoneExt":7,"email":76},"Samsung Medical Center hemato oncology","+82 2-3410-6856","kstwoh@skku.edu",{"name":78,"role":45,"phone":7,"phoneExt":7,"email":7},"SeokJin Kim",{"facility":80,"status":27,"city":49,"state":7,"zip":7,"country":31,"countryCode":7,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"Seoul National University Hospital",{"type":33,"coordinates":82},[52,53],{"lat":53,"lon":52},[85,89],{"name":86,"role":21,"phone":87,"phoneExt":7,"email":88},"Seoul National University Hospital hemato-oncology","+82 2 2072 0834","ihkimmd@snu.ac.kr",{"name":90,"role":45,"phone":7,"phoneExt":7,"email":7},"Kim in ho",{"facility":80,"status":27,"city":49,"state":7,"zip":7,"country":31,"countryCode":7,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},{"type":33,"coordinates":93},[52,53],{"lat":53,"lon":52},[96,99],{"name":86,"role":21,"phone":97,"phoneExt":7,"email":98},"+82 2-2072-4990","go01@snu.ac.kr",{"name":100,"role":45,"phone":7,"phoneExt":7,"email":7},"Youngil Koh",{"type":102,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100603134","assessment-of-safety-and-efficacy-of-poteligeo-inj-20-mg-mogamulizumab-through-use-result-surveillance-100603134",false,"NCT07132567","Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance","Inclusion Criteria:\n\n1. Adults 19 years of age or older\n2. Individuals who are confirmed to have received administration of the study drug for the purpose of \"the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies,\" or who are considered to require administration of the study drug in the investigator's opinion\n3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance\n\nExclusion Criteria\n\n1. Patients with hypersensitivity to any ingredients of this drug\n2. Patients who intend to use this drug for non-approved indications\n3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug","ALL","19 Years",{"count":112,"type":113},15,"ESTIMATED","OBSERVATIONAL","The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.",[117,118],"Mycosis Fungoides","Sezary Syndrome",[120,121,122],"Poteligeo","mycosis fungoides","Sezary syndrome","2025-09-19",{"date":125,"type":126},"2025-09-22","ACTUAL",{"date":128,"type":126},"2025-05-02",{"date":130,"type":113},"2028-11",{"name":5,"class":6},6]